This program aims to develop anti-GPC3 therapeutic vaccines for hepatocellular carcinoma immunotherapy.
Rationale for our program:
GPC3 is a heparan sulfate proteoglycan that binds to cell membranes by glycosylphosphatidylinositol (GPI) anchoring. GPC3 regulates cell proliferation signals by binding to growth factors such as Wnt, fibroblast growth factor and insulin-like growth factor, and plays an important role in the proliferation and differentiation of embryonic cells. GPC3 is overexpressed in HCC tissues but not overexpressed in normal and benign tissues. GPC3 appears to promote tumor cell proliferation and invasion, therefore, GPC3 may be a potential target for HCC immunotherapy.
Here are some published data about GPC3 working as a potential target for HCC immunotherapy.
(Wu, 2017)
Table 1. Ongoing clinical trials of the GPC3 vaccine against HCC. (Shimizu, 2019)
Creative Biolabs has extensive knowledge of end-to-end program development. For our Next-IOTM programs, we are committed to providing the program to the pre-IND stage within about 1.5 years.
Creative Biolabs is looking for potential partners (include but not limit to major pharma or biotech firms) to develop anti-GPC3 therapeutic vaccine program together. Our scientists are dedicated to bringing years of valuable experience to our partner and achieve a meaningful partnership together. For any partners interested in our Next-IO™ programs, Creative Biolabs welcomes collaboration.
Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from the discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate for our programs.
With our quality control protocol and knowledge of global regulatory requirements, we can help our partners to advance their programs with more chances to succeed. Look forward to cooperating with you in the near future.
For Research Use Only | Not For Clinical Use